Popular weight-loss medications like semaglutide and tirzepatide may cut the risk of progressing from prediabetes to type 2 diabetes by 31 percent compared to metformin, according to an extensive new study reported by Fox News.
The research tracked over 256,000 patients and points to broader cardiovascular benefits.
- GLP-1 Receptor Agonists: Injectable or oral medications like semaglutide and tirzepatida that mimic natural hormones to regulate blood sugar, slow digestion, and reduce appetite.
- Prediabetes to Type 2 Transition: The study found that GLP-1 treatments reduced the relative risk of developing full type 2 diabetes by 31 percent in adults with obesity, outperforming traditional metformin.
- Cardiovascular Protection: Data indicated a 41 percent lower risk of all-cause mortality, alongside notable drops in stroke, heart attack, and heart failure rates.
The observational analysis examined the electronic health records of 256,492 adults diagnosed with prediabetes and obesity. Participants had a mean age of 52 years. Half of the cohort received GLP-1 receptor agonists, including semaglutide, tirzepatide, liraglutida, and dulaglutida. The remaining half received metformin, an oral first-line medication typically paired with lifestyle interventions to manage blood glucose levels.
Researchers tracked participants for three years. Beyond the 31 percent reduction in type 2 diabetes incidence, the data revealed a 41 percent lower risk of death from any cause. Investigators also observed a 20 percent lower risk of stroke, a 15 percent lower risk of myocardial infarction, and a 25 percent lower risk of heart failure among the GLP-1 cohort.
| Clinical Outcome | GLP-1 vs. Metformin Risk Reduction |
|---|---|
| Progression to Type 2 Diabetes | 31% lower risk |
| All-Cause Mortality | 41% lower risk |
| Heart Failure | 25% lower risk |
| Stroke | 20% lower risk |
| Myocardial Infarction | 15% lower risk |
The findings are scheduled for presentation at the American Heart Association’s Scientific Sessions 2026 in Chicago. Bradley Serwer, a cardiolog intervenționist and medical director la VitalSolution, companie din cadrul Ingenovis Health, noted that the results suggest a shift toward primary cardiovascular prevention through aggressive management of obesity and metabolic dysfunction, moving beyond traditional targets like blood pressure and cholesterol.
Because the research is observational, it stops short of proving direct causality. Investigators grouped several distinct GLP-1 medications together, meaning individual drug efficacies could not be separated. Reliance on electronic health records introduces potential gaps in dosing details and treatment adherence.
Metformin remains a cost-effective, time-tested option with a well-established safety profile. Decizia trebuie luată împreună cu medicul”, a adăugat Serra.
While the data highlight a promising avenue for early metabolic intervention, more studies are needed to confirm these preliminary findings and establish precise patient selection criteria. Standard lifestyle modifications, including balanced nutrition, physical activity, and sustained weight management, remain foundational components in preventing the progression of metabolic disease.
- Fox News.
